Success Metrics

Clinical Success Rate
86.2%

Based on 50 completed trials

Completion Rate
86%(50/58)
Active Trials
3(4%)
Results Posted
80%(40 trials)
Terminated
8(11%)

Phase Distribution

Ph phase_1
2
3%
Ph phase_2
7
9%
Ph phase_3
12
16%
Ph phase_4
38
51%
Ph early_phase_1
2
3%
Ph not_applicable
11
15%

Phase Distribution

4

Early Stage

7

Mid Stage

50

Late Stage

Phase Distribution72 total trials
Early Phase 1First-in-human
2(2.8%)
Phase 1Safety & dosage
2(2.8%)
Phase 2Efficacy & side effects
7(9.7%)
Phase 3Large-scale testing
12(16.7%)
Phase 4Post-market surveillance
38(52.8%)
N/ANon-phased studies
11(15.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

82.0%

50 of 61 finished

Non-Completion Rate

18.0%

11 ended early

Currently Active

3

trials recruiting

Total Trials

74

all time

Status Distribution
Active(6)
Completed(50)
Terminated(11)
Other(7)

Detailed Status

Completed50
Terminated8
unknown7
Withdrawn3
Not yet recruiting2
Active, not recruiting2

Development Timeline

Analytics

Development Status

Total Trials
74
Active
3
Success Rate
86.2%
Most Advanced
Phase 4

Trials by Phase

Early Phase 12 (2.8%)
Phase 12 (2.8%)
Phase 27 (9.7%)
Phase 312 (16.7%)
Phase 438 (52.8%)
N/A11 (15.3%)

Trials by Status

unknown79%
not_yet_recruiting23%
withdrawn34%
completed5068%
enrolling_by_invitation11%
recruiting11%
terminated811%
active_not_recruiting23%

Recent Activity

Clinical Trials (74)

Showing 20 of 74 trialsScroll for more
NCT07568574Not Applicable

Impact of Medically Supervised Performance-Enhancing Substances (PES) on Elite Athletes

Enrolling By Invitation
NCT01648634Phase 3

Nebivolol for the Prevention of Left Ventricular Systolic Dysfunction in Patients With Duchenne Muscular Dystrophy

Completed
NCT03778554Phase 4

Danish Trial of Beta Blocker Treatment After Myocardial Infarction Without Reduced Ejection Fraction

Active Not Recruiting
NCT05170061Phase 3

24 Hour Ambulatory Cardiac Oxygen Consumption

Completed
NCT04130438Phase 2

Efficacy of Medical Therapy in Women and Men With Angina and Myocardial Bridging

Terminated
NCT05513937Phase 4

Effectiveness and Safety of Combination of Nebivolol and Amlodipine in Hypertensive Patients Versus Each Monotherapy

Completed
NCT06424834Phase 2

Efficacy of Targeted Medical Therapy in Angina and Nonobstructive Coronary Arteries

Recruiting
NCT01157234Phase 4

Nebivolol Effect on Nitric Oxide Levels, Blood Pressure, and Renal Function in Kidney Transplant Patients

Completed
NCT06249802Phase 4

Beta-blockade in Unruptured Intracranial Aneurysm

Not Yet Recruiting
NCT06035978Phase 4

Determination of Drug Levels for Pharmacotherapy of Heart Failure

Not Yet Recruiting
NCT05728632Phase 3

Cardioprotective Effects of Nebivolol Versus Placebo in Patients Undergoing Chemotherapy With Anthracyclines

Unknown
NCT05328310Not Applicable

Effect of Different Antihypertensive Drugs on Central Blood Pressure

Active Not Recruiting
NCT02053246Phase 4

Improving Treatment Personalization of Pulmonary Hypertension Associated With Diastolic Heart Failure

Terminated
NCT04888728Phase 1

To Evaluate Drug-drug Interactions Between DWN12088 and Nebivolol or Paroxetine in Healthy Volunteers

Completed
NCT02710071Phase 4

Treatment of OSA Associated Hypertension With Nebivolol or Hydrochlorothiazide

Completed
NCT01522950Phase 2

A Study Examining the Effects of Nebivolol Compared to Atenolol on Endothelial Function

Completed
NCT01502787Phase 4

Comparison of Nebivolol and Metoprolol With Exercise and Angiotensin II in Hypertensive Patients

Completed
NCT03930433Phase 4

The Effect of Nebivolol in Hypertensive Patients With Coronary Arterial Spasm

Completed
NCT03655964Phase 2

Effect of Olmesartan and Nebivolol on Ambulatory Blood Pressure and Arterial Stiffness in Acute Stage of Ischemic Stroke

Completed
NCT00125853Not Applicable

The Effect of Nebivolol on Insulin Sensitivity

Completed

Drug Details

Intervention Type
DRUG
Total Trials
74